NEWS
View news from our Featured Companies.
Kiora Pharmaceuticals Enters into Two Equity Purchase Agreements with Lincoln Park Capital
Encinitas, California--(February 3, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that it has entered into a common stock purchase agreement for a committed equity financing (the "Purchase Agreement") with Lincoln Park...
IRADIMED CORPORATION Announces Fourth Quarter and Full Year 2022 Financial Results and Announces Special Cash Dividend
Reports fourth quarter 2022 revenue of $14.9 million, GAAP diluted EPS of $0.29 and non-GAAP diluted EPS of $0.32.Reports full-year 2022 revenue of $53.3 million, GAAP diluted EPS of $1.02 and non-GAAP diluted EPS of $1.10.The Board of Directors approved a special...
Zoomd Technologies selected as one of the top two most interesting companies at the AlphaNorth Capital Conference
Zoomd received high praise with the highest scoring by capital investors at the January 2023 AlphaNorth Capital conference VANCOUVER, BC, Feb. 2, 2023 /CNW/ -- Zoomd Technologies Ltd. (TSXV: ZOMD) (OTC: ZMDTF) and its wholly-owned subsidiary Zoomd Ltd. (collectively,...
Cadrenal Therapeutics Announces Formation of Scientific Advisory Board
PONTE VEDRA, Fla., Feb. 1, 2023 -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, announced today the formation of its...
ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer’s Disease (AD) Patients
This first-of-its-kind human clinical study in AD patients showcased CMA supplementation significantly improved cognitive function and associated biomarkers LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced...
PolyPid to Report Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 8, 2023
PETACH TIKVA, Israel, Jan. 31, 2023 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full year 2022 financial results and...
Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference
Cupertino, Calif., Jan. 31, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Precision Optics to Present at Lytham Partners Investor Select Conference on January 31st
GARDNER, Mass., Jan. 27, 2023 -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced Dr. Joe Forkey, CEO, will present and host one-on-one...
Shuttle Pharmaceuticals to Present at Lytham Partners Investor Select Conference on January 31
ROCKVILLE, Md., Jan. 26, 2023 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced Anatoly...
IRADIMED CORPORATION to Hold 2022 Fourth Quarter Financial Results Conference Call on February 2nd
WINTER SPRINGS, Fla., Jan. 26, 2023 -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 fourth quarter financial results before the market opens on Thursday, February 2, 2023. IRADIMED management will host a conference call...
Albert AI Technology for Creative Optimization generates a 800% Return On Ad Spend
With ad creative optimization subject to user biases, like preferences for bold headlines, images, and colors, etc., Zoomd-owned Albert AI technology enables true creative optimization driven by real-time creative performance across products, ads, campaigns, and...
Modular Medical Provides Update on FDA Submission Strategy
SAN DIEGO, CA / January 25, 2023 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), a development stage insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today...
Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance
ENGLEWOOD, CO / January 25, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced...
SenesTech to Participate in the Lytham Partners Investor Select Conference
PHOENIX, Jan. 24, 2023 -- SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary technologies for managing animal pest populations through fertility control, announced today announced the management team will present and host one-on-one meetings with investors at...
Aytu BioPharma to Present at Lytham Partners Investor Select Conference on January 31
ENGLEWOOD, CO / January 24, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced...
PolyPid Provides Positive Regulatory Update for D-PLEX for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery
Regulatory Pathway for a Potential NDA Submission Clarified Following Recent Interactions with the FDA FDA Acknowledged that SHIELD I Pre-specified Subgroup Results May Provide Supportive Evidence and Proposed that Current SHIELD II Trial Could Potentially Serve to...
ARIANNE PHOSPHATE NAMES MARCO GAGNON AS CHAIRMAN AND ADDS DR. RAEF SULLY TO ITS BOARD OF DIRECTORS
SAGUENAY, QC, Jan. 24, 2023 /CNW Telbec/ - Arianne Phosphate (the "Company" or "Arianne") (TSXV: DAN) (OTC: DRRSF) (FRANKFURT: JE9N), a development-stage phosphate mining company, advancing its Lac à Paul project in Quebec's Saguenay-Lac-Saint-Jean region, is...
Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public Offering
PONTE VEDRA, Fla., Jan. 24, 2023 -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug indication, today announced the closing of its initial public...
Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation
PONTE VEDRA, Fla., Jan. 23, 2023 -- Cadrenal Therapeutics (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug designation, announced today that the U.S. Food and Drug Administration...
Scientific Industries to Present at the Maxim Healthcare IT Virtual Conference and Participate in Lytham Partners Investor Select Conference
Maxim Healthcare IT Conference - January 25th at 2:00 p.m. ETLytham Partners Investor Select Conference - January 31stBOHEMIA, NY / January 20, 2023 / Scientific Industries, Inc. (OTCQB:SCND), a life sciences tool provider and a developer of digitally simplified...
Cadrenal Therapeutics Announces Pricing of Initial Public Offering (IPO)
PONTE VEDRA, Fla., Jan. 20, 2023 -- Cadrenal Therapeutics, Inc., a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug designation, announced today the pricing of its initial public offering of...
IRADIMED CORPORATION Announces Preliminary Financial Results for Fourth Quarter 2022
Reports preliminary fourth quarter 2022 revenue of $14.9 millionAnnounces full-year and first-quarter 2023 financial guidance WINTER SPRINGS, Fla., Jan. 18, 2023 -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) today announced selected preliminary financial...
Jewett-Cameron Announces 1st Quarter Financial Results
NORTH PLAINS, Ore., Jan. 17, 2023 -- Jewett-Cameron Trading Company Ltd. (NASDAQ: JCTCF) today reported financial results for the first quarter of fiscal 2023 ended November 30, 2022. Sales for the first quarter of fiscal 2023 totaled $12.58 million compared to sales...
Shuttle Pharmaceuticals to Ring Nasdaq Opening Bell on Wednesday, January 18, 2023
ROCKVILLE, Md., Jan. 17, 2023 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced that...
Precision Optics Announces Receipt of $2.3 Million Follow-On Production Order from Large Medical Device Company for Otoscopy Application
GARDNER, Mass., Jan. 17, 2023 --. Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced the receipt of a follow-on production order totaling...